What Is Disease Modifying Therapy? Evidence-Based Disease Modification in Multiple Sclerosis

Released On
December 30, 2020

Expires On
December 30, 2021

Media Type
Internet

Completion Time
60 minutes

Specialty
Neurology, Pharmacy

Topic(s)
Multiple Sclerosis, Pharmacology

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by The Consortium of Multiple Sclerosis Centers and Catamount Medical Education.

This activity is supported by an independent educational grant from Sanofi Genzyme.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — maximum of 1.0 contact hours of continuing nursing education
  • Pharmacists — maximum of 1.0 contact hours of continuing pharmacy education

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of neurologists, nurses, nurse practitioners, PAs, pharmacists, and other members of the healthcare team essential to optimal management of patients with MS.

Program Overview

This interactive activity incorporates polling questions about common decision-making dilemmas in the treatment of multiple sclerosis (MS) with disease-modifying therapy. Following each polling question, our expert faculty will review relevant evidence and share examples of patient cases that illustrate considerations for starting, switching, and discontinuing therapy.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review evidence-based principles for setting treatment goals and starting disease-modifying therapy in patients diagnosed with MS
  • Employ approaches to evaluating treatment response and switching therapies when needed
  • Review considerations for stopping treatment in patients living with MS
  • Describe the effective team-based strategies that promote optimal patient outcomes

Faculty

Joseph R. Berger, MD, FACP, FAAN, FANA

Professor of Neurology and Associate Chief of the MS Division
Perelman School of Medicine
University of Pennsylvania

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physicans

The CMSC designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit Designation

The CMSC designates this activity for a maximum of 1.0 contact hours of continuing nursing education (1.0 in the area of pharmacology).

Pharmacists

This knowledge-based activity, UAN JA4008165-9999-20-071-H01-P, qualifies for 1.0 contact hours (.10 CEUs) of continuing pharmacy education credit.

Upon successful completion of the activity, your CE credits will be submitted electronically to the NABP CPE Monitor service. Paper certificates are not valid. For information about CPE Monitor, visit https://nabp.pharmacy/cpe-monitor-service/.

Disclosures of Conflicts of Interest

It is the policy of the Consortium of Multiple Sclerosis Centers (CMSC) to ensure balance, independence, objectivity, and scientific rigor in all educational activities. All faculty, planning committee members, content reviewers, and staff participating in this activity have disclosed any relevant financial relationships they or their significant other have had within the previous 12 months with manufacturers of any commercial products/devices and/or providers of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. All presentations were reviewed by an independent clinician with no relevant financial relationships for the purpose of resolution of any identified conflict of interest and a determination of evidence-base and fair balance.

Faculty Disclosures

Joseph R. Berger, MD, FACP, FAAN, FANA

  • Consulting Fees: Biogen, Celgene, Excision, Genentech/Roche, Inhibikase, Millennium/Takeda, Novartis, Sanofi Genzyme
  • Contracted Research: Biogen, Genentech/Roche

Activity Staff Disclosures

June Halper, MSN, APN-C, MSCN, FAAN, and Laurie Scudder, DNP, NP served as planners and reviewers and have declared that they have no relevant financial relationships to disclose.

All other planners, reviewers, staff, or other members of the Continuing Professional Education Committee at the Consortium of Multiple Sclerosis Centers who control content have disclosed no relevant financial relationships.

The planners, reviewers, editors, staff, CME committee, or other members at Catamount Medical Education who control content have disclosed no relevant financial relationships.

Instructions for Participation and Credit

This activity is an online enduring material. There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CME information, completing the pre-test, viewing the video, studying the educational activity and completing the post-test and the evaluation form. Upon completion of the evaluation, your certificate will be made available immediately. Click on "View Certificate" and print the certificate for your records.

The estimated time to complete the activity is 60 minutes.

This activity was originally released on December 30, 2020 and is eligible for credit through December 30, 2021.

Course Viewing Requirements

This site is best viewed with an HTML5 compatible browser. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser.

Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.

Our Policy on Privacy

The Consortium of Multiple Sclerosis Centers and Catamount Medical Education, LLC, respect your privacy. All personal information that is provided to Catamount Medical Education, LLC, is protected and will not be sold to a third party for commercial purposes. All personally identifiable information contained in the Catamount Medical Education, LLC, registration databases is treated as confidential and will be used only for the purposes stated in this policy, except where required by law. Catamount Medical Education, LLC, maintains user databases that contain mailing and user profile information as well as a record of the CME activities viewed and the post-test and evaluation results for CME/CE credit. This information is provided to activity collaborators for the purposes of CME/CE recordkeeping. By participating in this activity, you agree that Catamount Medical Education, LLC, has full permission to provide this information.

Catamount Medical Education, LLC, safeguards against the loss, misuse, or alteration of information that we have collected in this activity.

Disclosure of Unlabeled Use

CMSC and Catamount Medical Education require CME/CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

For questions about this activity, please contact Catamount Medical Education at info@catmeded.com.